- CentralReach has tapped investment bank William Blair to weigh a potential sale, BI has learned.
- The company makes electronic health records software for autism care.
- One person with knowledge of the efforts said CentralReach could seek a valuation of over $1 billion.
Autism care software maker CentralReach has been exploring a sale, Business Insider has learned.
CentralReach has tapped the investment bank William Blair to pursue a potential sale, according to people with knowledge of the efforts.
Founded in 2012, CentralReach sells electronic health records software to providers caring for autism and related intellectual and developmental disorders. The company also builds AI-powered tools within its platform to help providers automate tasks like reviewing clinical notes.
CentralReach and William Blair didn’t respond to requests for comment for this story.
Fort Lauderdale, Florida-based CentralReach has been publicly quiet about its financials to date. It’s backed by venture and private equity firm Insight Partners, which invested an undisclosed sum into CentralReach in 2018.
Two people with knowledge of CentralReach’s efforts said the company has soared as a market-leading maker of software for autism care. One of those people said CentralReach is doing about $75 million in earnings before deductions like taxes and interest.
That person said they expect CentralReach to seek a valuation north of $1 billion, based on current market standards.
A number of healthcare companies have been looking to sell themselves after a slow year for company combinations in 2024.
Investors and bankers told Business Insider in February that healthcare companies that are profitable and can demonstrate stable revenue will be far more attractive to buyers, especially private equity buyers.
Medical practice tech maker ModMed announced Monday that it sold a majority stake to PE firm Clearlake Capital from Warburg Pincus, which first invested in ModMed in 2017. The company didn’t disclose the terms of the acquisition, but the Financial Times reported the day before that the deal valued ModMed at $5.3 billion.
CentralReach has also made multiple acquisitions in the past few years, most recently buying Behavior Science Technology, which built a platform for measuring and tracking the efficacy of autism therapy, in September. In its 13-year history, CentralReach has made 14 acquisitions.
CentralReach said in a September release that its tech is used by more than 175,000 healthcare professionals globally.
